Viral Therapy in Treating Patient With Liver Cancer

Clinical Trial ID NCT01628640

PubWeight™ 35.19‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01628640

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2013 1.72
2 Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013 1.36
3 Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 2012 1.34
4 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
5 Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 2012 1.12
6 Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin 2015 0.92
7 Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res 2013 0.91
8 Long-distance interferon signaling within the brain blocks virus spread. J Virol 2014 0.90
9 Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther 2013 0.90
10 Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol 2013 0.89
11 The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. Mol Ther 2014 0.85
12 Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res 2013 0.84
13 Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol 2015 0.84
14 EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future 2016 0.84
15 Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget 2015 0.83
16 Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology 2015 0.83
17 Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther 2015 0.83
18 Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun 2015 0.82
19 Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol 2014 0.82
20 Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015 0.80
21 Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm. J Exp Clin Cancer Res 2014 0.80
22 How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity? Front Oncol 2014 0.80
23 Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma. Front Oncol 2014 0.80
24 Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology 2015 0.79
25 Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Gynecol Oncol 2013 0.79
26 Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV. Cancer Gene Ther 2013 0.79
27 Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck 2014 0.78
28 Cellular proteins associated with the interior and exterior of vesicular stomatitis virus virions. PLoS One 2014 0.78
29 Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Virology 2014 0.77
30 Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics 2015 0.77
31 Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. J Virol 2013 0.77
32 An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells. Virology 2015 0.77
33 Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin. J Virol 2013 0.76
34 PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model. Mol Ther 2015 0.76
35 Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer. J Virol 2015 0.75
36 Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors. Expert Opin Orphan Drugs 2015 0.75
37 Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity. Mol Ther Oncolytics 2015 0.75
38 Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. J Virol 2015 0.75
39 Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic Virother 2015 0.75
40 Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. Mol Ther Oncolytics 2016 0.75
41 The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virother 2015 0.75
Next 100